

Accelerating the Commercial Rollout of ColoSTAT®: 4Cyte Pathology Expands ColoSTAT® Collection Site Network

Highlights

- ✓ Following the successful validation of end-to-end testing workflow and the first commercial sale of its blood based ColoSTAT® colorectal cancer test, Rhythm Biosciences has successfully activated strategic collection centres with 4Cyte Pathology.
- ✓ 4Cyte Pathology has activated an initial network of thirty-eight blood collection sites across major cities in Queensland, New South Wales and Victoria enabling clinician referral and patient access to ColoSTAT® testing through an established clinician pathway at broad scale.
- ✓ Clinicians within designated 4Cyte Pathology clinics are being onboarded to provide referrals for ColoSTAT® testing, with additional collection sites planned as part of the ongoing commercial rollout.
- ✓ Immediate scale-up can now proceed directly with physicians and through the ColoSTAT® Access Program using a validated commercial and logistical pathway.

Melbourne, Australia, 18th March 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to report the successful activation of its first commercial blood collection network of clinics across major cities enabling the scaling of ColoSTAT® commercial testing services.

Rhythm previously announced the first commercial sale of ColoSTAT® and highlighted the importance of completing the end-to-end logistical and commercial process. Scaling of this process has commenced with the completion by 4Cyte Pathology (4Cyte) of the activation of blood collection sites across Queensland, New South Wales and Victoria, providing clinicians and patients in major metropolitan centres with direct access to the ColoSTAT® test.

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

These initial thirty-eight activated sites are in Melbourne, Sydney and Brisbane representing the first phase of Rhythm's broader commercial network rollout strategy with 4Cyte. These sites will be used by members of the ColoSTAT® Access Program as well as physician-directed prescribing of the ColoSTAT® test. Additional collection sites will be activated over the coming weeks.

The partnership with 4Cyte supports and accelerates rapid clinical awareness and promotion of ColoSTAT®, which brings commercial scale through leveraging 4Cyte's existing national pathology network and business development teams that work closely with referring clinicians and medical practices.

Additional sites are currently being activated across the 4Cyte network, with further progress and expansion tracked and reported via 4Cyte's online platform, thereby progressively expanding patient access to the test.

Commenting on the milestone, Rhythm's Managing Director and Chief Executive Officer, Dr David Atkins, said: "The activation of our collection centre network with 4Cyte across Queensland, New South Wales and Victoria marks a pivotal step in ColoSTAT®'s commercial journey. Having a validated, scalable pathway—from blood collection through to result reporting—means we can now focus our energy on building test volumes, both through direct engagement with primary care physicians and our ColoSTAT® Access Program."

Rhythm will provide regular updates on collection network growth and ColoSTAT® test volumes.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.